Three COPD drugs better than two? ask GSK/Theravance
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline and Theravance have begun a global Phase III study, known as IMPACT, to evaluate the efficacy and safety of the triple combination of three respiratory drugs in patients with chronic obstructive pulmonary disease (COPD).